Drug Type Degrader-antibody conjugates |
Synonyms |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization F5 Therapeutics, Inc.Startup |
Active Organization F5 Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | US | F5 Therapeutics, Inc.Startup | 10 Jan 2024 |
Head and Neck Neoplasms | Preclinical | US | F5 Therapeutics, Inc.Startup | 10 Jan 2024 |
Hepatocellular Carcinoma | Preclinical | US | F5 Therapeutics, Inc.Startup | 10 Jan 2024 |
Non-Small Cell Lung Cancer | Preclinical | US | F5 Therapeutics, Inc.Startup | 10 Jan 2024 |